These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 29526844)
21. Platelet-derived miR-103b as a novel biomarker for the early diagnosis of type 2 diabetes. Luo M; Li R; Deng X; Ren M; Chen N; Zeng M; Yan K; Xia J; Liu F; Ma W; Yang Y; Wan Q; Wu J Acta Diabetol; 2015 Oct; 52(5):943-9. PubMed ID: 25820527 [TBL] [Abstract][Full Text] [Related]
22. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study. Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441 [TBL] [Abstract][Full Text] [Related]
23. Endurance exercise training decreased serum levels of surfactant protein D and improved aerobic fitness of obese women with type-2 diabetes. Rezaei S; Shamsi MM; Mahdavi M; Jamali A; Prestes J; Tibana RA; Navalta JW; Voltarelli FA Diabetol Metab Syndr; 2017; 9():74. PubMed ID: 29021828 [TBL] [Abstract][Full Text] [Related]
24. Validation of a P2Y Amann M; Ferenc M; Valina CM; Bömicke T; Stratz C; Leggewie S; Trenk D; Neumann FJ; Hochholzer W Platelets; 2016 Nov; 27(7):668-672. PubMed ID: 27065056 [TBL] [Abstract][Full Text] [Related]
25. Effects of exercise training and deconditioning on platelet aggregation induced by alternating shear stress in men. Wang JS; Li YS; Chen JC; Chen YW Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):454-60. PubMed ID: 15569820 [TBL] [Abstract][Full Text] [Related]
26. The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays. Leunissen TC; Wisman PP; van Holten TC; de Groot PG; Korporaal SJ; Koekman AC; Moll FL; Teraa M; Verhaar MC; de Borst GJ; Urbanus RT; Roest M Platelets; 2017 Sep; 28(6):567-575. PubMed ID: 27885904 [TBL] [Abstract][Full Text] [Related]
27. Effects of pioglitazone and glipizide on platelet function in patients with type 2 diabetes. Xiao CC; Ren A; Yang J; Ye SD; Xing XN; Li SM; Chen C; Chen RP Eur Rev Med Pharmacol Sci; 2015; 19(6):963-70. PubMed ID: 25855920 [TBL] [Abstract][Full Text] [Related]
28. The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study. Schuette C; Steffens D; Witkowski M; Stellbaum C; Bobbert P; Schultheiss HP; Rauch U Cardiovasc Diabetol; 2015 Feb; 14():15. PubMed ID: 25645908 [TBL] [Abstract][Full Text] [Related]
29. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition. Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A Platelets; 2010; 21(7):563-70. PubMed ID: 20642320 [TBL] [Abstract][Full Text] [Related]
30. Controlled type II diabetes mellitus has no major influence on platelet micro-RNA expression. Results from micro-array profiling in a cohort of 60 patients. Stratz C; Nührenberg T; Fiebich BL; Amann M; Kumar A; Binder H; Hoffmann I; Valina C; Hochholzer W; Trenk D; Neumann FJ Thromb Haemost; 2014 May; 111(5):902-11. PubMed ID: 24352417 [TBL] [Abstract][Full Text] [Related]
31. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography. Khanna V; Armstrong PC; Warner TD; Curzen N Platelets; 2015; 26(7):689-92. PubMed ID: 25734957 [TBL] [Abstract][Full Text] [Related]
32. The role of agonist-induced activation and inhibition for the regulation of purinergic receptor expression in human platelets. Koessler J; Trulley VN; Bosch A; Weber K; Koessler A; Boeck M; Kobsar A Thromb Res; 2018 Aug; 168():40-46. PubMed ID: 29902630 [TBL] [Abstract][Full Text] [Related]
33. Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS. Peng L; Liu J; Qin L; Liu J; Xi S; Lu C; Yin T Thromb Res; 2017 Sep; 157():97-102. PubMed ID: 28734158 [TBL] [Abstract][Full Text] [Related]
34. Impact of chronic kidney disease on platelet P2Y Engwenyu LR; Franchi F; Rollini F; Cho JR; DeGroat C; Bhatti M; Alobaidi Z; Ferrante E; Jakubowski JA; Sugidachi A; Zenni M; Bass TA; Angiolillo DJ Thromb Haemost; 2017 Jan; 117(1):201-203. PubMed ID: 27786340 [No Abstract] [Full Text] [Related]
35. Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel. Yang HH; Chen Y; Gao CY Cardiovasc Ther; 2016 Dec; 34(6):460-467. PubMed ID: 27566695 [TBL] [Abstract][Full Text] [Related]
36. Role of P2Y Zhang Y; Zhang S; Ding Z Adv Exp Med Biol; 2017; 906():307-324. PubMed ID: 27628007 [TBL] [Abstract][Full Text] [Related]
37. P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes. Matsuno H; Tokuda H; Ishisaki A; Zhou Y; Kitajima Y; Kozawa O J Clin Endocrinol Metab; 2005 Feb; 90(2):920-7. PubMed ID: 15483100 [TBL] [Abstract][Full Text] [Related]
38. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906 [TBL] [Abstract][Full Text] [Related]
39. The Emerging Role of miR-223 in Platelet Reactivity: Implications in Antiplatelet Therapy. Shi R; Zhou X; Ji WJ; Zhang YY; Ma YQ; Zhang JQ; Li YM Biomed Res Int; 2015; 2015():981841. PubMed ID: 26221610 [TBL] [Abstract][Full Text] [Related]
40. Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. van der Meijden PE; Feijge MA; Giesen PL; Huijberts M; van Raak LP; Heemskerk JW Thromb Haemost; 2005 Jun; 93(6):1128-36. PubMed ID: 15968399 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]